https://novapharmanews.com/apac/news/xtalpi-pep08-prmt5-inhibitor-phase-1-cancer-trial-enrollment 2026-05-04T21:17:29.885Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:17:29.885Z XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment https://novapharmanews.com/uploads/articles/xtalpi-pep08-prmt5-inhibitor-phase-1-cancer-trial-enrollment.webp XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment https://novapharmanews.com/apac/news/spontan-phase-ii-data-10-minute-onset-fda-requirements-erectile-dysfunction 2026-05-04T22:16:00.252Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:17:19.213Z SPONTAN Phase II Data Shows 10-Minute Onset Time, Meets FDA Requirements for Erectile Dysfunction Treatment https://novapharmanews.com/uploads/articles/spontan-phase-ii-data-10-minute-onset-fda-requirements-erectile-dysfunction.webp SPONTAN Phase II Data Shows 10-Minute Onset Time, Meets FDA Requirements for Erectile Dysfunction Treatment https://novapharmanews.com/apac/news/ironwood-pharmaceuticals-short-bowel-syndrome-tpn-survey-ddw-2026 2026-05-04T23:13:04.860Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:16:57.513Z Ironwood Pharmaceuticals Survey Reveals Critical Gaps in Short Bowel Syndrome TPN Treatment at DDW 2026 https://novapharmanews.com/uploads/articles/ironwood-pharmaceuticals-short-bowel-syndrome-tpn-survey-ddw-2026.webp Ironwood Pharmaceuticals Survey Reveals Critical Gaps in Short Bowel Syndrome TPN Treatment at DDW 2026 https://novapharmanews.com/apac/news/edwards-lifesciences-resilia-tissue-10-year-commence-trial-results 2026-05-04T23:09:33.949Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:16:22.727Z Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in COMMENCE Aortic Trial Results https://novapharmanews.com/uploads/articles/edwards-lifesciences-resilia-tissue-10-year-commence-trial-results.webp Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in COMMENCE Aortic Trial Results https://novapharmanews.com/apac/news/novo-nordisk-wegovy-china-launch-eli-lilly-obesity-market 2026-05-04T23:18:19.886Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:16:20.835Z Novo Nordisk Launches Wegovy in China Before Eli Lilly, Capturing World's Largest Obesity Market https://novapharmanews.com/uploads/articles/novo-nordisk-wegovy-china-launch-eli-lilly-obesity-market.webp Novo Nordisk Launches Wegovy in China Before Eli Lilly, Capturing World's Largest Obesity Market https://novapharmanews.com/apac/news/arrowhead-pharmaceuticals-tga-approval-redemplo-plozasiran-australia-fcs 2026-05-04T23:12:25.562Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:15:28.387Z Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Genetic Disorder https://novapharmanews.com/uploads/articles/arrowhead-pharmaceuticals-tga-approval-redemplo-plozasiran-australia-fcs.webp Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Genetic Disorder https://novapharmanews.com/apac/news/biomarin-palynziq-fda-approval-adolescent-pku-patients 2026-05-04T23:13:06.231Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:15:04.650Z BioMarin's PALYNZIQ Receives FDA Approval for Adolescent PKU Patients 12 and Older https://novapharmanews.com/uploads/articles/biomarin-palynziq-fda-approval-adolescent-pku-patients.webp BioMarin's PALYNZIQ Receives FDA Approval for Adolescent PKU Patients 12 and Older https://novapharmanews.com/apac/news/rois-us-expansion-global-cdmo-fda-approval-injectable-manufacturing 2026-05-04T22:15:08.575Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:14:55.579Z ROIS Expands to US Market as Global CDMO with FDA Approval for Injectable Drug Manufacturing https://novapharmanews.com/uploads/articles/rois-us-expansion-global-cdmo-fda-approval-injectable-manufacturing.webp ROIS Expands to US Market as Global CDMO with FDA Approval for Injectable Drug Manufacturing https://novapharmanews.com/apac/news/fda-approves-travere-filspari-fsgs-treatment-adults-children 2026-05-04T23:12:51.032Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:14:09.600Z FDA Approves Travere's FILSPARI for FSGS Treatment in Adults and Children 8+ https://novapharmanews.com/uploads/articles/fda-approves-travere-filspari-fsgs-treatment-adults-children.webp FDA Approves Travere's FILSPARI for FSGS Treatment in Adults and Children 8+ https://novapharmanews.com/eu/news/vanda-pharmaceuticals-nereus-tradipitant-motion-sickness-drug-launch 2026-05-04T23:08:37.503Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:14:01.328Z Vanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now Available https://novapharmanews.com/uploads/articles/vanda-pharmaceuticals-nereus-tradipitant-motion-sickness-drug-launch.webp Vanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now Available https://novapharmanews.com/eu/news/takeda-tak-881-phase-3-trial-primary-immunodeficiency-disease-results 2026-05-04T23:13:38.076Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:13:28.315Z Takeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease https://novapharmanews.com/uploads/articles/takeda-tak-881-phase-3-trial-primary-immunodeficiency-disease-results.webp Takeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease https://novapharmanews.com/eu/news/pulse-biosciences-atrial-fibrillation-treatment-100-percent-success-rate-2026 2026-05-04T23:12:51.199Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:13:07.806Z Pulse Biosciences Reports 100% Success Rate in Atrial Fibrillation Treatment Trial at Heart Rhythm 2026 https://novapharmanews.com/uploads/articles/pulse-biosciences-atrial-fibrillation-treatment-100-percent-success-rate-2026.webp Pulse Biosciences Reports 100% Success Rate in Atrial Fibrillation Treatment Trial at Heart Rhythm 2026 https://novapharmanews.com/eu/news/sq-innovation-lasix-onyu-subcut-hf-ii-trial-results-heart-failure-2026 2026-05-04T23:14:57.312Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:12:47.033Z SQ Innovation's Lasix ONYU Subcutaneous Heart Failure Trial Results to Be Presented at Heart Failure 2026 https://novapharmanews.com/uploads/articles/sq-innovation-lasix-onyu-subcut-hf-ii-trial-results-heart-failure-2026.webp SQ Innovation's Lasix ONYU Subcutaneous Heart Failure Trial Results to Be Presented at Heart Failure 2026 https://novapharmanews.com/eu/news/krystal-biotech-q1-2026-results-vyjuvek-expansion-registrational-studies 2026-05-04T23:08:59.420Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:12:24.994Z Krystal Biotech Reports Strong Q1 2026 Results with VYJUVEK Global Expansion and Two Registrational Studies Pending https://novapharmanews.com/uploads/articles/krystal-biotech-q1-2026-results-vyjuvek-expansion-registrational-studies.webp Krystal Biotech Reports Strong Q1 2026 Results with VYJUVEK Global Expansion and Two Registrational Studies Pending https://novapharmanews.com/eu/news/acurx-dna-pol-iiic-inhibitors-microbiome-preservation-mrsa-escmid-2026 2026-05-04T23:17:06.763Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:12:13.267Z Acurx DNA pol IIIC Inhibitors Show Gut Microbiome Preservation in MRSA Treatment Study at ESCMID Global 2026 https://novapharmanews.com/uploads/articles/acurx-dna-pol-iiic-inhibitors-microbiome-preservation-mrsa-escmid-2026.webp Acurx DNA pol IIIC Inhibitors Show Gut Microbiome Preservation in MRSA Treatment Study at ESCMID Global 2026 https://novapharmanews.com/eu/news/biocryst-navenibart-european-licensing-deal-neopharmed-gentili 2026-05-04T23:12:57.958Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:11:34.136Z BioCryst Secures $70M Upfront in European Licensing Deal for Navenibart Hereditary Angioedema Treatment https://novapharmanews.com/uploads/articles/biocryst-navenibart-european-licensing-deal-neopharmed-gentili.webp BioCryst Secures $70M Upfront in European Licensing Deal for Navenibart Hereditary Angioedema Treatment https://novapharmanews.com/eu/news/biosimulation-market-11-billion-2031-drug-development 2026-05-04T23:16:10.619Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:11:01.029Z Biosimulation Market to Reach $11.3 Billion by 2031 as Pharmaceutical Companies Accelerate Digital Drug Development https://novapharmanews.com/uploads/articles/biosimulation-market-11-billion-2031-drug-development.webp Biosimulation Market to Reach $11.3 Billion by 2031 as Pharmaceutical Companies Accelerate Digital Drug Development https://novapharmanews.com/eu/news/grin-therapeutics-phase-3-beeline-study-radiprodil-europe-grin-ndd 2026-05-04T22:14:49.240Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:10:50.384Z GRIN Therapeutics Expands Phase 3 Beeline Study for Radiprodil to Europe for GRIN-NDD Treatment https://novapharmanews.com/uploads/articles/grin-therapeutics-phase-3-beeline-study-radiprodil-europe-grin-ndd.webp GRIN Therapeutics Expands Phase 3 Beeline Study for Radiprodil to Europe for GRIN-NDD Treatment https://novapharmanews.com/eu/news/fda-approves-langlara-biosimilar-lantus-insulin-lannett-company 2026-05-04T23:08:38.406Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:10:15.364Z FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval https://novapharmanews.com/uploads/articles/fda-approves-langlara-biosimilar-lantus-insulin-lannett-company.webp FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval https://novapharmanews.com/eu/news/vertex-casgevy-gene-therapy-global-expansion-q1-2026-results 2026-05-04T23:15:24.051Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:09:44.026Z Vertex CASGEVY Gene Therapy Reaches 60,000+ Eligible Patients Across 10 Countries as Q1 2026 Results Show Global Expansion https://novapharmanews.com/uploads/articles/vertex-casgevy-gene-therapy-global-expansion-q1-2026-results.webp Vertex CASGEVY Gene Therapy Reaches 60,000+ Eligible Patients Across 10 Countries as Q1 2026 Results Show Global Expansion https://novapharmanews.com/eu/news/oncolytics-biotech-pelareorep-durable-responses-ras-mutant-colorectal-cancer 2026-05-04T23:13:33.598Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:09:14.671Z Oncolytics Biotech Pelareorep Shows Durable Responses in RAS-Mutant Colorectal Cancer Trial https://novapharmanews.com/uploads/articles/oncolytics-biotech-pelareorep-durable-responses-ras-mutant-colorectal-cancer.webp Oncolytics Biotech Pelareorep Shows Durable Responses in RAS-Mutant Colorectal Cancer Trial https://novapharmanews.com/eu/news/nuvation-bio-ibtrozi-q1-2026-revenue-ros1-nsclc 2026-05-04T23:13:07.496Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:09:05.890Z Nuvation Bio's IBTROZI Generates $18.5M Revenue in Q1 2026, Shows Strong First-Line Adoption in ROS1+ NSCLC https://novapharmanews.com/uploads/articles/nuvation-bio-ibtrozi-q1-2026-revenue-ros1-nsclc.webp Nuvation Bio's IBTROZI Generates $18.5M Revenue in Q1 2026, Shows Strong First-Line Adoption in ROS1+ NSCLC https://novapharmanews.com/us/news/crispr-therapeutics-casgevy-global-approvals-60000-patients 2026-05-04T23:14:58.054Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:08:28.176Z CRISPR Therapeutics' CASGEVY Reaches 60,000+ Eligible Patients Across 10 Countries Following Global Approvals https://novapharmanews.com/uploads/articles/crispr-therapeutics-casgevy-global-approvals-60000-patients.webp CRISPR Therapeutics' CASGEVY Reaches 60,000+ Eligible Patients Across 10 Countries Following Global Approvals https://novapharmanews.com/us/news/clene-cnm-au8-fda-accelerated-approval-pathway-als-treatment 2026-05-04T23:14:49.803Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:07:56.203Z Clene's CNM-Au8 Gets FDA Green Light for Accelerated Approval Pathway in ALS Treatment https://novapharmanews.com/uploads/articles/clene-cnm-au8-fda-accelerated-approval-pathway-als-treatment.webp Clene's CNM-Au8 Gets FDA Green Light for Accelerated Approval Pathway in ALS Treatment https://novapharmanews.com/us/news/atossa-therapeutics-fda-rare-pediatric-disease-designation-z-endoxifen-mccune-albright-syndrome 2026-05-04T22:46:39.830Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:07:47.490Z Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen in McCune-Albright Syndrome https://novapharmanews.com/uploads/articles/atossa-therapeutics-fda-rare-pediatric-disease-designation-z-endoxifen-mccune-albright-syndrome.webp Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen in McCune-Albright Syndrome https://novapharmanews.com/us/news/mbiota-elemental-ibs-treatment-ddw-2026-clinical-trial 2026-05-04T23:17:57.305Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:07:06.345Z mBIOTA Elemental Diet Shows Promise for IBS Treatment in New Clinical Trial Data Presented at DDW 2026 https://novapharmanews.com/uploads/articles/mbiota-elemental-ibs-treatment-ddw-2026-clinical-trial.webp mBIOTA Elemental Diet Shows Promise for IBS Treatment in New Clinical Trial Data Presented at DDW 2026 https://novapharmanews.com/us/news/novartis-fabhalta-health-canada-approval-c3g-treatment 2026-05-04T21:06:46.384Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:06:46.384Z Novartis Receives Health Canada Approval for Fabhalta Oral Treatment for C3G Patients https://novapharmanews.com/uploads/articles/novartis-fabhalta-health-canada-approval-c3g-treatment.webp Novartis Receives Health Canada Approval for Fabhalta Oral Treatment for C3G Patients https://novapharmanews.com/us/news/asco-2026-cellectar-waldenstrom-macroglobulinemia 2026-05-04T23:17:45.830Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:06:45.729Z ASCO 2026: Cellectar's Waldenström Macroglobulinemia Data https://novapharmanews.com/uploads/articles/asco-2026-cellectar-waldenstrom-macroglobulinemia.webp ASCO 2026: Cellectar's Waldenström Macroglobulinemia Data https://novapharmanews.com/us/news/alpha-tau-alpha-dart-pancreatic-cancer-trials-ddw-2026 2026-05-04T23:12:27.294Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:06:20.926Z Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026 https://novapharmanews.com/uploads/articles/alpha-tau-alpha-dart-pancreatic-cancer-trials-ddw-2026.webp Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026 https://novapharmanews.com/us/news/cytokinetics-aficamten-phase-3-trial-results-non-obstructive-hypertrophic-cardiomyopathy-may-2026 2026-05-04T23:14:59.754Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:05:49.827Z Cytokinetics to Report Aficamten Phase 3 Trial Results for Non-Obstructive Hypertrophic Cardiomyopathy May 5, 2026 https://novapharmanews.com/uploads/articles/cytokinetics-aficamten-phase-3-trial-results-non-obstructive-hypertrophic-cardiomyopathy-may-2026.webp Cytokinetics to Report Aficamten Phase 3 Trial Results for Non-Obstructive Hypertrophic Cardiomyopathy May 5, 2026 https://novapharmanews.com/us/news/inflarx-izicopan-reactive-metabolite-liver-safety-study 2026-05-04T23:12:56.461Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:05:22.655Z InflaRx Izicopan Shows Low Reactive Metabolite Formation in Liver Safety Study https://novapharmanews.com/uploads/articles/inflarx-izicopan-reactive-metabolite-liver-safety-study.webp InflaRx Izicopan Shows Low Reactive Metabolite Formation in Liver Safety Study https://novapharmanews.com/us/news/macrogenics-expands-zynyz-royalty-agreement-sagard-healthcare 2026-05-04T23:15:01.489Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:05:13.838Z MacroGenics Expands ZYNYZ Royalty Agreement with Sagard Healthcare Partners for Cancer Drug https://novapharmanews.com/uploads/articles/macrogenics-expands-zynyz-royalty-agreement-sagard-healthcare.webp MacroGenics Expands ZYNYZ Royalty Agreement with Sagard Healthcare Partners for Cancer Drug https://novapharmanews.com/us/news/akebia-vadadustat-mortality-reduction-kidney-disease-jasn-study 2026-05-04T23:15:12.114Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:04:53.822Z Akebia Therapeutics Vadadustat Shows Significant Mortality Reduction in New Kidney Disease Analysis https://novapharmanews.com/uploads/articles/akebia-vadadustat-mortality-reduction-kidney-disease-jasn-study.webp Akebia Therapeutics Vadadustat Shows Significant Mortality Reduction in New Kidney Disease Analysis https://novapharmanews.com/us/news/inflarx-izicopan-favorable-liver-metabolism-safety-profile-2026 2026-05-04T23:09:16.939Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:04:22.004Z InflaRx Reports Favorable Safety Profile for Izicopan in Liver Metabolism Study https://novapharmanews.com/uploads/articles/inflarx-izicopan-favorable-liver-metabolism-safety-profile-2026.webp InflaRx Reports Favorable Safety Profile for Izicopan in Liver Metabolism Study https://novapharmanews.com/us/news/celcuity-gedatolisib-phase-3-viktoria-1-trial-pik3ca-mutant-cancer 2026-05-04T23:13:55.894Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:03:26.697Z Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial https://novapharmanews.com/uploads/articles/celcuity-gedatolisib-phase-3-viktoria-1-trial-pik3ca-mutant-cancer.webp Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial https://novapharmanews.com/us/news/fda-approves-langlara-interchangeable-biosimilar-lantus-insulin-lannett 2026-05-04T23:16:20.065Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:02:53.481Z FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market https://novapharmanews.com/uploads/articles/fda-approves-langlara-interchangeable-biosimilar-lantus-insulin-lannett.webp FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market https://novapharmanews.com/us/news/fda-approves-guardant360-cdx-companion-diagnostic-pfizer-veppanu-breast-cancer 2026-05-04T23:12:24.898Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:02:14.515Z FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer https://novapharmanews.com/uploads/articles/fda-approves-guardant360-cdx-companion-diagnostic-pfizer-veppanu-breast-cancer.webp FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer https://novapharmanews.com/us/news/fda-approves-incyte-jakafi-xr-extended-release-myelofibrosis 2026-05-04T23:17:51.301Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:01:50.675Z FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders https://novapharmanews.com/uploads/articles/fda-approves-incyte-jakafi-xr-extended-release-myelofibrosis.webp FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders https://novapharmanews.com/us/news/arvinas-veppanu-vepdegestrant-fda-approval-first-protac-drug-esr1-breast-cancer 2026-05-04T22:16:12.881Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:01:28.213Z Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer https://novapharmanews.com/uploads/articles/arvinas-veppanu-vepdegestrant-fda-approval-first-protac-drug-esr1-breast-cancer.webp Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer https://novapharmanews.com/us/news/excipient-world-conference-daily-roundup 2026-05-04T23:17:48.348Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T20:02:13.689Z Excipient World Conference: Key Highlights and Industry Trends https://novapharmanews.com/uploads/articles/excipient-world-conference-daily-roundup.webp Excipient World Conference: Key Highlights and Industry Trends https://novapharmanews.com/us/news/APHL-2026-annual-meeting-day-1-highlights 2026-05-04T23:17:26.281Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T16:00:35.928Z APHL 2026 Annual Meeting: Day 1 Highlights https://novapharmanews.com/uploads/articles/APHL-2026-annual-meeting-day-1-highlights.webp APHL 2026 Annual Meeting: Day 1 Highlights https://novapharmanews.com/us/news/aphl-2026-day-1-roundup 2026-05-04T23:17:12.770Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T12:00:31.547Z APHL 2026: Day 1 Highlights and Key Takeaways https://novapharmanews.com/uploads/articles/aphl-2026-day-1-roundup.webp APHL 2026: Day 1 Highlights and Key Takeaways https://novapharmanews.com/eu/news/swiss-biotech-day-daily-roundup 2026-05-04T23:09:42.959Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T08:01:51.242Z Swiss Biotech Day: Key Takeaways and Industry Trends https://novapharmanews.com/uploads/articles/swiss-biotech-day-daily-roundup.webp Swiss Biotech Day: Key Takeaways and Industry Trends https://novapharmanews.com/apac/news/fda-approves-auvelity-new-mdd-treatment 2026-05-04T23:12:21.867Z hourly 0.9 NovaPharmaNews en 2026-05-04T07:08:39.207Z FDA Approves Auvelity: A New Option for MDD https://novapharmanews.com/uploads/articles/fda-approves-auvelity-new-mdd-treatment.webp FDA Approves Auvelity: A New Option for MDD https://novapharmanews.com/apac/news/sun-pharma-organon-partnership-india 2026-05-04T23:12:03.904Z hourly 0.9 NovaPharmaNews en 2026-05-04T07:08:09.439Z Sun Pharma Organon Partnership to Expand Access to Key Medicines https://novapharmanews.com/uploads/articles/sun-pharma-organon-partnership-india.webp Sun Pharma Organon Partnership to Expand Access to Key Medicines https://novapharmanews.com/eu/news/fda-approves-auvelity-mdd-axsome-therapeutics 2026-05-04T23:09:43.956Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T07:05:54.602Z FDA Approves Auvelity for MDD: Axsome Therapeutics Scores Win https://novapharmanews.com/uploads/articles/fda-approves-auvelity-mdd-axsome-therapeutics.webp FDA Approves Auvelity for MDD: Axsome Therapeutics Scores Win https://novapharmanews.com/eu/news/purdue-pharma-shutdown-oxycontin-settlement 2026-05-04T23:13:12.994Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T07:04:18.946Z Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations https://novapharmanews.com/uploads/articles/purdue-pharma-shutdown-oxycontin-settlement.webp Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations https://novapharmanews.com/us/news/fda-approves-palazestrant-pfizer-arvinas-breast-cancer-drug 2026-05-04T23:10:45.070Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T07:02:27.732Z FDA Approves Palazestrant for Breast Cancer Amidst Data Concerns https://novapharmanews.com/uploads/articles/fda-approves-palazestrant-pfizer-arvinas-breast-cancer-drug.webp FDA Approves Palazestrant for Breast Cancer Amidst Data Concerns https://novapharmanews.com/eu/news/eular-2026-immutep-imp761-phase-1-preview 2026-05-04T23:15:11.186Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T05:03:13.771Z EULAR 2026: Immutep's IMP761 Phase I Data Preview https://novapharmanews.com/uploads/articles/eular-2026-immutep-imp761-phase-1-preview.webp EULAR 2026: Immutep's IMP761 Phase I Data Preview https://novapharmanews.com/us/news/thma-pharmacy-growth-priorities-2026 2026-05-04T23:12:55.004Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T05:02:27.663Z THMA Pharmacy Growth Priorities 2026: Key Insights for CPOs https://novapharmanews.com/uploads/articles/thma-pharmacy-growth-priorities-2026.webp THMA Pharmacy Growth Priorities 2026: Key Insights for CPOs https://novapharmanews.com/us/news/cphi-americas-2026-pharma-manufacturing-trends 2026-05-04T12:49:12.169Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T05:00:41.745Z CPhI Americas 2026: Pharma Manufacturing Trends in Philadelphia https://novapharmanews.com/uploads/articles/cphi-americas-2026-pharma-manufacturing-trends.webp CPhI Americas 2026: Pharma Manufacturing Trends in Philadelphia https://novapharmanews.com/us/news/ipec-americas-annual-meeting-daily-roundup 2026-05-04T23:17:24.782Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T04:02:03.608Z IPEC Americas Annual Meeting: Key Takeaways for Pharma https://novapharmanews.com/uploads/articles/ipec-americas-annual-meeting-daily-roundup.webp IPEC Americas Annual Meeting: Key Takeaways for Pharma https://novapharmanews.com/us/news/excipient-world-conference-day-1-highlights 2026-05-04T23:14:58.730Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T04:01:18.901Z Excipient World Conference: Day 1 Highlights https://novapharmanews.com/uploads/articles/excipient-world-conference-day-1-highlights.webp Excipient World Conference: Day 1 Highlights https://novapharmanews.com/us/news/aphl-2026-annual-day-1-roundup 2026-05-04T22:14:00.567Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T04:00:32.252Z APHL 2026 Annual Meeting: Key Takeaways from Day 1 https://novapharmanews.com/uploads/articles/aphl-2026-annual-day-1-roundup.webp APHL 2026 Annual Meeting: Key Takeaways from Day 1 https://novapharmanews.com/apac/news/ucb-acquires-candid-therapeutics-2-2-billion-t-cell-engager-autoimmune 2026-05-04T12:49:12.654Z hourly 0.9 NovaPharmaNews en 2026-05-04T03:03:42.696Z UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases https://novapharmanews.com/uploads/articles/ucb-acquires-candid-therapeutics-2-2-billion-t-cell-engager-autoimmune.webp UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases https://novapharmanews.com/eu/news/novelty-nobility-agc-biologics-bispecific-antibody-manufacturing-partnership 2026-05-04T23:16:36.178Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T03:02:58.961Z Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing https://novapharmanews.com/uploads/articles/novelty-nobility-agc-biologics-bispecific-antibody-manufacturing-partnership.webp Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing https://novapharmanews.com/eu/news/smartee-denti-technology-mandibular-repositioning-eas-congress-2026 2026-05-04T23:09:09.435Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T03:02:39.548Z Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026 https://novapharmanews.com/uploads/articles/smartee-denti-technology-mandibular-repositioning-eas-congress-2026.webp Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026 https://novapharmanews.com/us/news/xtalpi-pep08-prmt5-inhibitor-phase-1-cancer-trial-enrollment 2026-05-04T23:14:02.690Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:02:18.090Z XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment https://novapharmanews.com/uploads/articles/xtalpi-pep08-prmt5-inhibitor-phase-1-cancer-trial-enrollment.webp XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment https://novapharmanews.com/us/news/mirum-pharmaceuticals-vistas-volixibat-primary-sclerosing-cholangitis-results-may-2026 2026-05-04T22:14:46.402Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:01:56.836Z Mirum Pharmaceuticals VISTAS Study Results for Volixibat in Primary Sclerosing Cholangitis Due May 4, 2026 https://novapharmanews.com/uploads/articles/mirum-pharmaceuticals-vistas-volixibat-primary-sclerosing-cholangitis-results-may-2026.webp Mirum Pharmaceuticals VISTAS Study Results for Volixibat in Primary Sclerosing Cholangitis Due May 4, 2026 https://novapharmanews.com/us/news/everads-therapy-suprachoroidal-injector-clinical-data-ophthalmology-science 2026-05-04T23:14:25.579Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:01:31.010Z Everads Therapy Publishes First-in-Human Clinical Data for Suprachoroidal Injector in Ophthalmology Science https://novapharmanews.com/uploads/articles/everads-therapy-suprachoroidal-injector-clinical-data-ophthalmology-science.webp Everads Therapy Publishes First-in-Human Clinical Data for Suprachoroidal Injector in Ophthalmology Science https://novapharmanews.com/us/news/ucb-acquires-candid-therapeutics-autoimmune-deal 2026-05-04T23:15:17.853Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:01:05.077Z UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal https://novapharmanews.com/uploads/articles/ucb-acquires-candid-therapeutics-autoimmune-deal.webp UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal https://novapharmanews.com/us/news/spinogenix-tazbentetol-neuroprotective-glaucoma-diabetic-retinopathy-arvo-2026 2026-05-04T22:16:01.817Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:00:41.363Z Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026 https://novapharmanews.com/uploads/articles/spinogenix-tazbentetol-neuroprotective-glaucoma-diabetic-retinopathy-arvo-2026.webp Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026 https://novapharmanews.com/us/news/niktimvo-axatilimab-approved-australia-chronic-gvhd-treatment 2026-05-04T23:15:34.875Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:00:20.396Z NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment https://novapharmanews.com/uploads/articles/niktimvo-axatilimab-approved-australia-chronic-gvhd-treatment.webp NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment https://novapharmanews.com/us/news/ipec-annual-meeting-2026-no-pharma-news 2026-05-04T23:18:51.406Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T00:04:53.441Z IPEC Annual Meeting 2026: No Pharma News Today https://novapharmanews.com/uploads/articles/ipec-annual-meeting-2026-no-pharma-news.webp IPEC Annual Meeting 2026: No Pharma News Today https://novapharmanews.com/eu/news/swiss-biotech-day-2026-ai-oncology-microbiome 2026-05-04T23:09:41.958Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T00:03:42.558Z Swiss Biotech Day 2026: AI, Oncology, Microbiome Highlights https://novapharmanews.com/uploads/articles/swiss-biotech-day-2026-ai-oncology-microbiome.webp Swiss Biotech Day 2026: AI, Oncology, Microbiome Highlights https://novapharmanews.com/us/news/excipient-world-conference-2026-daily-roundup 2026-05-04T12:50:11.435Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T00:02:59.839Z Excipient World Conference 2026: No Pharma Breaking News https://novapharmanews.com/uploads/articles/excipient-world-conference-2026-daily-roundup.webp Excipient World Conference 2026: No Pharma Breaking News https://novapharmanews.com/us/news/aphl-2026-annual-meeting-opens-public-health-lab-focus 2026-05-04T23:17:13.207Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T00:00:53.404Z APHL 2026 Annual Meeting Opens: Public Health Lab Focus https://novapharmanews.com/uploads/articles/aphl-2026-annual-meeting-opens-public-health-lab-focus.webp APHL 2026 Annual Meeting Opens: Public Health Lab Focus https://novapharmanews.com/apac/news/fda-approves-auvelity-mdd-new-antidepressant 2026-05-04T23:12:42.223Z hourly 0.9 NovaPharmaNews en 2026-05-03T07:07:55.125Z FDA Approves Auvelity for MDD: A New Antidepressant Option https://novapharmanews.com/uploads/articles/fda-approves-auvelity-mdd-new-antidepressant.webp FDA Approves Auvelity for MDD: A New Antidepressant Option https://novapharmanews.com/eu/news/purdue-pharma-dissolution-approved-opioid-crisis 2026-05-04T23:09:19.442Z hourly 0.9 NovaPharmaNews en-GB 2026-05-03T07:05:42.135Z Purdue Pharma Dissolution Approved: What It Means for Opioid Crisis https://novapharmanews.com/uploads/articles/purdue-pharma-dissolution-approved-opioid-crisis.webp Purdue Pharma Dissolution Approved: What It Means for Opioid Crisis https://novapharmanews.com/eu/news/auvelity-fda-approval-axsome-therapeutics 2026-05-04T23:14:01.741Z hourly 0.9 NovaPharmaNews en-GB 2026-05-03T07:05:33.583Z Auvelity FDA Approval: New Hope for MDD Patients https://novapharmanews.com/uploads/articles/auvelity-fda-approval-axsome-therapeutics.webp Auvelity FDA Approval: New Hope for MDD Patients https://novapharmanews.com/us/news/axsome-fda-approval-alzheimers-agitation 2026-05-04T23:14:12.840Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T07:03:11.831Z Axsome FDA Approval for Alzheimer's Agitation Drug https://novapharmanews.com/uploads/articles/axsome-fda-approval-alzheimers-agitation.webp Axsome FDA Approval for Alzheimer's Agitation Drug https://novapharmanews.com/us/news/fda-approves-first-non-antipsychotic-dementia-agitation 2026-05-04T23:15:16.362Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T07:03:10.612Z FDA Approves First Non-Antipsychotic for Dementia Agitation https://novapharmanews.com/uploads/articles/fda-approves-first-non-antipsychotic-dementia-agitation.webp FDA Approves First Non-Antipsychotic for Dementia Agitation https://novapharmanews.com/apac/news/a2-milk-company-recalls-platinum-infant-formula-health-risk 2026-05-04T23:15:00.519Z hourly 0.9 NovaPharmaNews en 2026-05-03T03:04:15.228Z a2 Milk Company Recalls Three Batches of a2 Platinum Infant Formula Due to Health Risk Concerns https://novapharmanews.com/uploads/articles/a2-milk-company-recalls-platinum-infant-formula-health-risk.webp a2 Milk Company Recalls Three Batches of a2 Platinum Infant Formula Due to Health Risk Concerns https://novapharmanews.com/us/news/edwards-lifesciences-resilia-tissue-10-year-durability-aortic-valve-trial 2026-05-04T23:17:19.524Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T03:02:02.521Z Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in Pivotal Aortic Valve Trial https://novapharmanews.com/uploads/articles/edwards-lifesciences-resilia-tissue-10-year-durability-aortic-valve-trial.webp Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in Pivotal Aortic Valve Trial https://novapharmanews.com/us/news/biomarin-voxzogo-achondroplasia-long-term-data-pes-2026 2026-05-04T23:15:18.355Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T03:01:25.239Z BioMarin VOXZOGO Shows Long-Term Benefits for Achondroplasia in New Clinical Data at PES 2026 https://novapharmanews.com/uploads/articles/biomarin-voxzogo-achondroplasia-long-term-data-pes-2026.webp BioMarin VOXZOGO Shows Long-Term Benefits for Achondroplasia in New Clinical Data at PES 2026 https://novapharmanews.com/us/news/fda-approves-incyte-jakafi-xr-extended-release-myelofibrosis-polycythemia-vera 2026-05-04T23:17:52.844Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T03:00:36.859Z FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment https://novapharmanews.com/uploads/articles/fda-approves-incyte-jakafi-xr-extended-release-myelofibrosis-polycythemia-vera.webp FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment